31 July 2018 | News
Trazimera is the third biosimilar version of Roche's Herceptin in Europe.
Singapore – The European Commission approves Pfizer's TRAZIMERA, a biosimilar of Roche's cancer med Herceptin (trastuzumab).
TRAZIMERA, a potential biosimilar to Herceptin (trastuzumab), targets the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
The advisory group CHMP adopted a positive opinion backing approval in May.